Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced or Metastatic Non‑Small‑Cell Lung Cancer Reaching Primary Endpoint

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced or Metastatic Non‑Small‑Cell Lung Cancer Reaching Primary Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis